Goldman Sachs
ADPT icon

Goldman Sachs’s Adaptive Biotechnologies ADPT Stock Holding History

Goldman Sachs’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-107,400
Closed -$1.25M – 6301
2025
Q2 		$1.25M Buy
+107,400
New +$976K ﹤0.01% 4531

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs's ADPT Position: Q2 2026 in Review

Goldman Sachs reduced its Adaptive Biotechnologies (ADPT) stake by 8% in Q2 2026, selling an estimated $3.95M and leaving 2,984,227 shares worth $64M. The position accounts for 0.01% of the portfolio, ranked #1598.

Goldman Sachs first reported a position in ADPT in Q2 2019 and has held it in 29 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Goldman Sachs held 2,984,227 shares of Adaptive Biotechnologies worth $64M as of Q2 2026.
  • Goldman Sachs sold 257,850 Adaptive Biotechnologies shares in Q2 2026, an estimated $3.95M.
  • Adaptive Biotechnologies made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1598 holding.
  • Goldman Sachs first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 29 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.